Literature DB >> 18420736

Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat.

Scott G Kurz1, Kimberly K Hansen, Mac T McLaughlin, Vijay Shivaswamy, Beverly S Schaffer, Karen A Gould, Rodney D McComb, Jane L Meza, James D Shull.   

Abstract

Ept1, Ept2, Ept6, and Ept9 are quantitative trait loci mapped in crosses between the ACI and Copenhagen (COP) rat strains as genetic determinants of responsiveness of the pituitary gland to estrogens. We have developed four congenic rat strains, each of which carries, on the genetic background of the ACI rat strain, alleles from the COP rat strain that span one of these quantitative trait loci. Relative to the female ACI rats, female ACI.COP-Ept1 rats exhibited reduced responsiveness to 17beta-estradiol (E2) in the pituitary gland, as evidenced by quantification of pituitary mass and circulating prolactin, and in the mammary gland, as evidenced by reduced susceptibility to E2-induced mammary cancer. The ACI.COP-Ept2 rat strain exhibited reduced responsiveness to E2 in the pituitary gland but did not differ from the ACI strain in regard to susceptibility to E2-induced mammary cancer. Interestingly, female Ept2 congenic rats exhibited increased responsiveness to E2 in the thymus, as evidenced by enhanced thymic atrophy. The ACI.COP-Ept6 rat strain exhibited increased responsiveness to E2 in the pituitary gland, which was associated with a qualitative phenotype suggestive of enhanced pituitary vascularization. The ACI.COP-Ept9 rat strain exhibited reduced responsiveness to E2 in the anterior pituitary gland, relative to the ACI rat strain. Neither Ept6 nor Ept9 impacted responsiveness to E2 in the mammary gland or thymus. These data indicate that each of these Ept genetic determinants of estrogen action is unique in regard to the tissues in which it exerts its effects and/or the direction of its effect on estrogen responsiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420736      PMCID: PMC2488241          DOI: 10.1210/en.2008-0173

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

1.  Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma.

Authors:  J D Shull; T J Spady; M C Snyder; S L Johansson; K L Pennington
Journal:  Carcinogenesis       Date:  1997-08       Impact factor: 4.944

Review 2.  Speed congenics: a classic technique in the fast lane (relatively speaking).

Authors:  E Wakeland; L Morel; K Achey; M Yui; J Longmate
Journal:  Immunol Today       Date:  1997-10

3.  17 beta-Estradiol inhibits the production of dopamine by the tuberoinfundibular dopaminergic neurons of the male rat.

Authors:  C M Shaw-Bruha; H K Happe; L C Murrin; J F Rodriguez-Sierra; J D Shull
Journal:  Brain Res Bull       Date:  1996       Impact factor: 4.077

Review 4.  Estrogens and the genetic control of tumor growth.

Authors:  J Gorski; D Wendell; D Gregg; T Y Chun
Journal:  Prog Clin Biol Res       Date:  1997

5.  Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.

Authors:  S K Banerjee; D K Sarkar; A P Weston; A De; D R Campbell
Journal:  Carcinogenesis       Date:  1997-06       Impact factor: 4.944

6.  Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.

Authors:  D L Wendell; A Herman; J Gorski
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice.

Authors:  K A Gould; W F Dietrich; N Borenstein; E S Lander; W F Dove
Journal:  Genetics       Date:  1996-12       Impact factor: 4.562

8.  Estrogen-induced tumorigenesis in the Copenhagen rat: disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas.

Authors:  T J Spady; D M Harvell; M C Snyder; K L Pennington; R D McComb; J D Shull
Journal:  Cancer Lett       Date:  1998-02-13       Impact factor: 8.679

9.  Quantitative trait loci for estrogen-dependent pituitary tumor growth in the rat.

Authors:  D L Wendell; J Gorski
Journal:  Mamm Genome       Date:  1997       Impact factor: 2.957

Review 10.  The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis.

Authors:  James D Shull
Journal:  Breast Dis       Date:  2007
View more
  16 in total

1.  Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism.

Authors:  Harini S Aiyer; Ramesh C Gupta
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-25

2.  Dietary tocopherols inhibit cell proliferation, regulate expression of ERα, PPARγ, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia.

Authors:  Amanda K Smolarek; Jae Young So; Paul E Thomas; Hong Jin Lee; Shiby Paul; Anne Dombrowski; Chung-Xiou Wang; Constance Lay-Lay Saw; Tin Oo Khor; Ah-Ng Tony Kong; Kenneth Reuhl; Mao-Jung Lee; Chung S Yang; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

Review 3.  The role of genetics in estrogen responses: a critical piece of an intricate puzzle.

Authors:  Emma H Wall; Sylvia C Hewitt; Laure K Case; Chin-Yo Lin; Kenneth S Korach; Cory Teuscher
Journal:  FASEB J       Date:  2014-09-11       Impact factor: 5.191

4.  Tocopherols inhibit oxidative and nitrosative stress in estrogen-induced early mammary hyperplasia in ACI rats.

Authors:  Soumyasri Das Gupta; Jae Young So; Brian Wall; Joseph Wahler; Amanda K Smolarek; Sudathip Sae-Tan; Kelvin Y Soewono; Haixiang Yu; Mao-Jung Lee; Paul E Thomas; Chung S Yang; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2014-04-30       Impact factor: 4.784

5.  Ept7 influences estrogen action in the pituitary gland and body weight of rats.

Authors:  Scott G Kurz; Kirsten L Dennison; Nyssa Becker Samanas; Maureen Peters Hickman; Quincy A Eckert; Tiffany L Walker; Andrea S Cupp; James D Shull
Journal:  Mamm Genome       Date:  2014-01-22       Impact factor: 2.957

6.  Dietary γ-Tocopherol-Rich Mixture Inhibits Estrogen-Induced Mammary Tumorigenesis by Modulating Estrogen Metabolism, Antioxidant Response, and PPARγ.

Authors:  Soumyasri Das Gupta; Sudathip Sae-tan; Joseph Wahler; Jae Young So; Min Ji Bak; Larry C Cheng; Mao-Jung Lee; Yong Lin; Weichung Joe Shih; James D Shull; Stephen Safe; Chung S Yang; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-30

Review 7.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

8.  CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.

Authors:  Michael J Flister; Bradley T Endres; Nathan Rudemiller; Allison B Sarkis; Stephanie Santarriaga; Ishan Roy; Angela Lemke; Aron M Geurts; Carol Moreno; Sophia Ran; Shirng-Wern Tsaih; Jeffery De Pons; Daniel F Carlson; Wenfang Tan; Scott C Fahrenkrug; Zelmira Lazarova; Jozef Lazar; Paula E North; Peter S LaViolette; Michael B Dwinell; James D Shull; Howard J Jacob
Journal:  Cancer Res       Date:  2014-08-29       Impact factor: 12.701

9.  Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model.

Authors:  Rachel L Ruhlen; Dana M Willbrand; Cynthia L Besch-Williford; Lixin Ma; James D Shull; Edward R Sauter
Journal:  Breast Cancer Res Treat       Date:  2008-09-09       Impact factor: 4.872

Review 10.  Genetic variation in sensitivity to estrogens and breast cancer risk.

Authors:  D Joseph Jerry; James D Shull; Darryl L Hadsell; Monique Rijnkels; Karen A Dunphy; Sallie S Schneider; Laura N Vandenberg; Prabin Dhangada Majhi; Celia Byrne; Amy Trentham-Dietz
Journal:  Mamm Genome       Date:  2018-02-27       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.